TelyRx Holdings Inc.
TELY.TO
TSX
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | 16.02% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 16.02% | ||||
| Cost of Revenue | -36.96% | ||||
| Gross Profit | 73.52% | ||||
| SG&A Expenses | 99.98% | ||||
| Depreciation & Amortization | 154.49% | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 28.82% | ||||
| Operating Income | -195.36% | ||||
| Income Before Tax | -190.93% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -192.63% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -192.63% | ||||
| EBIT | -195.36% | ||||
| EBITDA | -199.12% | ||||
| EPS Basic | -192.53% | ||||
| Normalized Basic EPS | -191.11% | ||||
| EPS Diluted | -190.00% | ||||
| Normalized Diluted EPS | -191.11% | ||||
| Average Basic Shares Outstanding | 0.00% | ||||
| Average Diluted Shares Outstanding | 0.00% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||